Idexx Laboratories (IDXX)

$561.17 -0.99 (-0.18%)
Market Cap 44.34B
Revenue (ttm) 4.30B
Net Income (ttm) 1.06B
EPS (ttm) N/A
PE Ratio 41.59
Forward PE 38.46
Profit Margin 24.62%
Debt to Equity Ratio 0.29
Volume 370,500
Avg Vol 600,550
Day's Range N/A - N/A
Shares Out 78.88M
Stochastic %K 45%
Beta 1.55
Analysts Strong Sell
Price Target $731.54

Company Profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 207 556 0300
Fax: 207 556 4346
Address:
One IDEXX Drive, Westbrook, United States
AIBioScanner
AIBioScanner Jun. 8 at 7:58 AM
$IDXX AI-Based Findings on IDXX After running IDXX through my AI-driven quantitative framework, the stock is in a sideways/mixed trend with price trading near both moving averages with no clear directional pressure. IDXX is trading around $562.16, near both the 20-day (~$550.98) and 50-day (~$563.09) moving averages — indicating indecision and softening structure. Key signals: • Trading near both MAs — sideways/mixed trend • MACD negative (-0.26) — bearish momentum • Range between ~$528.68 support and ~$591.84 resistance 1-Month Outlook: Base scenario: consolidation near $534.05–$590.27 Breakout above $590.27 could open a move toward $690.61 Breakdown below $534.05 may extend further downside toward $437.92 Structure is neutral-to-mixed. Requires strong volume confirmation for any reversal. Not financial advice.$IDXX
0 · Reply
MarketBeat
MarketBeat May. 30 at 11:02 AM
https://marketbeat.com/a/8683841/ $IDXX IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference
0 · Reply
BillionerOfKing
BillionerOfKing May. 25 at 9:17 PM
$IDXX Current Stock Price: $559.38 Contracts to trade: $560.0 IDXX Jun 18 2026 Call Entry: $18.00 Exit: $24.97 ROI: 39% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize May. 25 at 2:00 PM
Wall St is expecting 3.96 EPS for $IDXX Q2 [Reporting 08/04 BMO] http://www.estimize.com/intro/idxx?chart=historical&metric_name=eps&utm_co
0 · Reply
CapitalMonk
CapitalMonk May. 20 at 5:49 AM
$IDXX Price: $546.49 (+0.13%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.99% RSI: 46.9 | Momentum: Moderate Volume: +11.3% vs avg Volatility: 2.03% Support: $523.38 | Resistance: $585.12 Sourch: http://marketbaubles.com/
0 · Reply
falcon_trader11
falcon_trader11 May. 18 at 6:15 PM
Not many small biotech names can reference relationships tied to $JNJ and $IDXX . $HYFT ecosystem keeps getting more interesting.
0 · Reply
bullishbears
bullishbears May. 13 at 5:30 PM
Veterinary stocks are gaining attention as pet ownership and animal healthcare spending continue to grow. Companies like Zoetis ($ZTS), IDEXX Laboratories ($IDXX), PetIQ ($PETQ), and Trupanion ($TRUP) are helping shape the future of the veterinary and pet care industry. From diagnostics and pharmaceuticals to pet insurance and wellness products, these stocks give investors exposure to a growing market driven by strong consumer demand and long-term trends. Check out our full breakdown of top veterinary stocks to watch and learn how traders and investors are approaching this sector. https://bullishbears.com/veterinary-stocks/
0 · Reply
MyChicago
MyChicago May. 13 at 4:02 PM
$ZOMDF Zomedica May Momentum CEO Larry Heaton and Johnny D Powers, both added shares in May 2026, direct insider confidence right after Zomedica reported record Q1 revenue of $8.8 million, up 35% YoY with $47.5 million in liquidity. Insiders don’t buy unless they believe in the next leg up. $IDXX $AMZN $ELAN
2 · Reply
Arcides
Arcides May. 11 at 5:02 PM
$IDXX another health care stock with new breakdown...
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 4:44 PM
$IDXX Current Stock Price: $536.65 Contracts to trade: $540.0 IDXX May 15 2026 Call Entry: $6.30 Exit: $9.98 ROI: 58% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on IDXX
IDEXX Laboratories Transcript: Stifel Jaws & Paws Conference 2026

May 27, 2026, 10:55 AM EDT - 12 days ago

IDEXX Laboratories Transcript: Stifel Jaws & Paws Conference 2026

Idexx Laboratories expands Fecal Dx platform for taeniid tapeworm detection

2026-05-26T12:01:58.000Z - 13 days ago

Idexx Laboratories expands Fecal Dx platform for taeniid tapeworm detection

IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection

May 26, 2026, 7:00 AM EDT - 13 days ago

IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection

Idexx Laboratories announces SDMA to be built into Catalyst CLIPs

2026-05-19T11:06:50.000Z - 20 days ago

Idexx Laboratories announces SDMA to be built into Catalyst CLIPs

IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles

May 19, 2026, 7:00 AM EDT - 20 days ago

IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles

IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day

May 14, 2026, 4:34 PM EDT - 25 days ago

IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day

IDEXX Laboratories Transcript: AGM 2026

May 12, 2026, 10:00 AM EDT - 27 days ago

IDEXX Laboratories Transcript: AGM 2026

Idexx Laboratories price target lowered to $660 from $790 at BofA

2026-05-05T19:20:19.000Z - 4 weeks ago

Idexx Laboratories price target lowered to $660 from $790 at BofA

IDEXX Laboratories Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 weeks ago

IDEXX Laboratories Earnings Call Transcript: Q1 2026

IDEXX Laboratories Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 weeks ago

IDEXX Laboratories Earnings release: Q1 2026

IDEXX Laboratories Slides: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 weeks ago

IDEXX Laboratories Slides: Q1 2026

IDEXX Laboratories Quarterly report: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 weeks ago

IDEXX Laboratories Quarterly report: Q1 2026

Idexx Laboratories reports Q1 EPS $3.47, consensus $3.41

2026-05-05T10:53:57.000Z - 4 weeks ago

Idexx Laboratories reports Q1 EPS $3.47, consensus $3.41

Idexx Laboratories raises FY26 EPS view to $14.45-$14.90 from $14.29-$14.80

2026-05-05T10:51:27.000Z - 4 weeks ago

Idexx Laboratories raises FY26 EPS view to $14.45-$14.90 from $14.29-$14.80

IDEXX Laboratories Announces First Quarter Results

May 5, 2026, 6:30 AM EDT - 4 weeks ago

IDEXX Laboratories Announces First Quarter Results

Idexx Laboratories price target lowered to $640 from $730 at UBS

2026-04-28T13:14:55.000Z - 5 weeks ago

Idexx Laboratories price target lowered to $640 from $730 at UBS

University of New England launches new Institute of Public and Planetary Health in honor of philanthropist and IDEXX Founder David Evans Shaw

Apr 27, 2026, 11:40 AM EDT - 6 weeks ago

University of New England launches new Institute of Public and Planetary Health in honor of philanthropist and IDEXX Founder David Evans Shaw

Idexx Laboratories initiated with a Neutral at Citi

2026-04-15T10:26:57.000Z - 7 weeks ago

Idexx Laboratories initiated with a Neutral at Citi

IDEXX Laboratories to Release 2026 First Quarter Financial Results

Apr 8, 2026, 1:00 PM EDT - 2 months ago

IDEXX Laboratories to Release 2026 First Quarter Financial Results

Idexx Laboratories announces Idexx Cancer Dx Panel availability in the UK

2026-04-01T09:15:31.000Z - 2 months ago

Idexx Laboratories announces Idexx Cancer Dx Panel availability in the UK

IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma

Apr 1, 2026, 3:00 AM EDT - 2 months ago

IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma

Idexx Laboratories price target lowered to $675 from $775 at Stifel

2026-03-31T10:44:57.000Z - 2 months ago

Idexx Laboratories price target lowered to $675 from $775 at Stifel

IDEXX Laboratories Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 2 months ago

IDEXX Laboratories Proxy statement: Proxy filing

IDEXX Laboratories Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 2 months ago

IDEXX Laboratories Proxy statement: Proxy filing

Idexx Laboratories management to meet with Piper Sandler

2026-03-26T19:45:14.000Z - 2 months ago

Idexx Laboratories management to meet with Piper Sandler

IDEXX Laboratories Proxy statement: Proxy Filing

Mar 13, 2026, 8:00 AM EDT - 3 months ago

IDEXX Laboratories Proxy statement: Proxy Filing

IDEXX Laboratories Transcript: 47th Annual Raymond James Institutional Investor Conference

Mar 2, 2026, 9:15 AM EST - 3 months ago

IDEXX Laboratories Transcript: 47th Annual Raymond James Institutional Investor Conference

IDEXX Laboratories Slides: 47th Annual Raymond James Institutional Investor Conference

Mar 2, 2026, 9:15 AM EST - 3 months ago

IDEXX Laboratories Slides: 47th Annual Raymond James Institutional Investor Conference

IDEXX Laboratories Transcript: BofA Securities Animal Health Summit

Feb 26, 2026, 9:50 AM EST - 3 months ago

IDEXX Laboratories Transcript: BofA Securities Animal Health Summit

IDEXX Laboratories to Present at Two Institutional Investor Conferences

Feb 12, 2026, 4:15 PM EST - 4 months ago

IDEXX Laboratories to Present at Two Institutional Investor Conferences

Idexx Laboratories price target lowered to $750 from $775 at Piper Sandler

2026-02-09T11:55:29.000Z - 4 months ago

Idexx Laboratories price target lowered to $750 from $775 at Piper Sandler

Idexx Laboratories price target lowered to $800 from $850 at Barclays

2026-02-05T10:45:55.000Z - 4 months ago

Idexx Laboratories price target lowered to $800 from $850 at Barclays

Idexx Laboratories price target lowered to $730 from $750 at UBS

2026-02-03T12:10:52.000Z - 4 months ago

Idexx Laboratories price target lowered to $730 from $750 at UBS

Idexx Laboratories price target lowered to $800 from $830 at BTIG

2026-02-03T02:10:10.000Z - 4 months ago

Idexx Laboratories price target lowered to $800 from $830 at BTIG

IDEXX Laboratories Earnings Call Transcript: Q4 2025

Feb 2, 2026, 8:30 AM EST - 4 months ago

IDEXX Laboratories Earnings Call Transcript: Q4 2025

IDEXX Laboratories Annual report: Q4 2025

Feb 2, 2026, 8:30 AM EST - 4 months ago

IDEXX Laboratories Annual report: Q4 2025

IDEXX Laboratories Earnings release: Q4 2025

Feb 2, 2026, 8:30 AM EST - 4 months ago

IDEXX Laboratories Earnings release: Q4 2025

IDEXX Laboratories Slides: Q4 2025

Feb 2, 2026, 8:30 AM EST - 4 months ago

IDEXX Laboratories Slides: Q4 2025

IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics

Feb 2, 2026, 8:12 AM EST - 4 months ago

IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics

Idexx Laboratories reports Q4 EPS $3.08, consensus $2.94

2026-02-02T11:35:45.000Z - 4 months ago

Idexx Laboratories reports Q4 EPS $3.08, consensus $2.94

Idexx Laboratories sees FY26 EPS $14.29-$14.80, consensus $14.45

2026-02-02T11:35:23.000Z - 4 months ago

Idexx Laboratories sees FY26 EPS $14.29-$14.80, consensus $14.45

IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results

Feb 2, 2026, 6:30 AM EST - 4 months ago

IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results

Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus

Jan 15, 2026, 7:15 AM EST - 5 months ago

Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus

IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs

Jan 15, 2026, 7:00 AM EST - 5 months ago

IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs

IDEXX Announces CEO Succession

Jan 13, 2026, 8:30 AM EST - 5 months ago

IDEXX Announces CEO Succession

IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results

Jan 9, 2026, 1:30 PM EST - 5 months ago

IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results

Final Trades: Palo Alto Networks, Capital One, Idexx Labs and the XLB

Jan 7, 2026, 1:51 PM EST - 5 months ago

Final Trades: Palo Alto Networks, Capital One, Idexx Labs and the XLB

COF PANW XLB

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

Nov 24, 2025, 2:15 PM EST - 7 months ago

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

RMD

Final Trades: Meta, S&P Global and Idexx Lab

Nov 3, 2025, 1:29 PM EST - 7 months ago

Final Trades: Meta, S&P Global and Idexx Lab

META SPGI

Idexx Stock Pops on Earnings. Pet Health Is Booming.

Nov 3, 2025, 11:08 AM EST - 7 months ago

Idexx Stock Pops on Earnings. Pet Health Is Booming.

IDEXX Laboratories Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:30 AM EST - 7 months ago

IDEXX Laboratories Earnings Call Transcript: Q3 2025

IDEXX Laboratories Quarterly report: Q3 2025

Nov 3, 2025, 8:30 AM EST - 7 months ago

IDEXX Laboratories Quarterly report: Q3 2025

IDEXX Laboratories Earnings release: Q3 2025

Nov 3, 2025, 8:30 AM EST - 7 months ago

IDEXX Laboratories Earnings release: Q3 2025

IDEXX Laboratories Slides: Q3 2025

Nov 3, 2025, 8:30 AM EST - 7 months ago

IDEXX Laboratories Slides: Q3 2025

IDEXX raises annual forecasts as pet owners spend more on preventive care

Nov 3, 2025, 7:43 AM EST - 7 months ago

IDEXX raises annual forecasts as pet owners spend more on preventive care

IDEXX Laboratories Announces Third Quarter Results

Nov 3, 2025, 6:30 AM EST - 7 months ago

IDEXX Laboratories Announces Third Quarter Results

IDEXX Laboratories to Release 2025 Third Quarter Financial Results

Oct 8, 2025, 2:00 PM EDT - 8 months ago

IDEXX Laboratories to Release 2025 Third Quarter Financial Results

IDEXX Laboratories Elects Karen Peacock to Board of Directors

Oct 7, 2025, 7:00 AM EDT - 8 months ago

IDEXX Laboratories Elects Karen Peacock to Board of Directors

IDEXX Laboratories Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 1:50 PM EDT - 9 months ago

IDEXX Laboratories Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

IDEXX Laboratories to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 1:00 PM EDT - 9 months ago

IDEXX Laboratories to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

IDEXX Laboratories Transcript: Investor Day 2025

Aug 14, 2025, 8:00 AM EDT - 10 months ago

IDEXX Laboratories Transcript: Investor Day 2025

IDEXX Laboratories Slides: FY 2025

Aug 14, 2025, 8:00 AM EDT - 10 months ago

IDEXX Laboratories Slides: FY 2025

S&P 500 Gains and Losses Today: Retail Sector Stocks Rise Amid Rate Cut Hopes

Aug 4, 2025, 5:55 PM EDT - 11 months ago

S&P 500 Gains and Losses Today: Retail Sector Stocks Rise Amid Rate Cut Hopes

Final Trades: Delta Air Lines, Tesla, Idexx Lab and the IYF

Aug 4, 2025, 1:48 PM EDT - 11 months ago

Final Trades: Delta Air Lines, Tesla, Idexx Lab and the IYF

DAL IYF TSLA

Top Stock Movers Now: IDEXX, Wayfair, Berkshire Hathaway, and More

Aug 4, 2025, 12:15 PM EDT - 11 months ago

Top Stock Movers Now: IDEXX, Wayfair, Berkshire Hathaway, and More

W

IDEXX Laboratories Stock Jumps as Pet Health Care Firm Lifts Full-Year Outlook

Aug 4, 2025, 9:10 AM EDT - 11 months ago

IDEXX Laboratories Stock Jumps as Pet Health Care Firm Lifts Full-Year Outlook

IDEXX Laboratories Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

IDEXX Laboratories Earnings Call Transcript: Q2 2025

IDEXX Laboratories Quarterly report: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

IDEXX Laboratories Quarterly report: Q2 2025

IDEXX Laboratories Earnings release: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

IDEXX Laboratories Earnings release: Q2 2025

IDEXX Laboratories Slides: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

IDEXX Laboratories Slides: Q2 2025

IDEXX Laboratories raises annual forecasts on strong demand for pet diagnostics

Aug 4, 2025, 7:57 AM EDT - 11 months ago

IDEXX Laboratories raises annual forecasts on strong demand for pet diagnostics

IDEXX Laboratories Announces Second Quarter Results

Aug 4, 2025, 6:30 AM EDT - 11 months ago

IDEXX Laboratories Announces Second Quarter Results

IDEXX Releases 2024 Corporate Responsibility Report, Highlighting Progress Against Its Goals

Jul 30, 2025, 7:00 AM EDT - 11 months ago

IDEXX Releases 2024 Corporate Responsibility Report, Highlighting Progress Against Its Goals

IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

Jul 10, 2025, 7:00 AM EDT - 11 months ago

IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

IDEXX Laboratories to Release 2025 Second Quarter Financial Results

Jun 24, 2025, 1:00 PM EDT - 1 year ago

IDEXX Laboratories to Release 2025 Second Quarter Financial Results

Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders

IDEXX Laboratories Transcript: Stifel Jaws & Paws Conference 2025

May 28, 2025, 10:55 AM EDT - 1 year ago

IDEXX Laboratories Transcript: Stifel Jaws & Paws Conference 2025

IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day

May 13, 2025, 2:30 PM EDT - 1 year ago

IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day

IDEXX Laboratories Earnings Call Transcript: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

IDEXX Laboratories Earnings Call Transcript: Q1 2025

IDEXX Laboratories Quarterly report: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

IDEXX Laboratories Quarterly report: Q1 2025

IDEXX Laboratories Earnings release: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

IDEXX Laboratories Earnings release: Q1 2025

IDEXX Laboratories Slides: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

IDEXX Laboratories Slides: Q1 2025

IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics

May 1, 2025, 8:21 AM EDT - 1 year ago

IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics

IDEXX Laboratories to Release 2025 First Quarter Financial Results

Apr 3, 2025, 1:30 PM EDT - 1 year ago

IDEXX Laboratories to Release 2025 First Quarter Financial Results

IDEXX Laboratories Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

IDEXX Laboratories Proxy statement: Proxy Filing

IDEXX Laboratories Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

IDEXX Laboratories Proxy statement: Proxy Filing

IDEXX Laboratories Proxy statement: Proxy Filing

Mar 14, 2025, 8:00 AM EDT - 1 year ago

IDEXX Laboratories Proxy statement: Proxy Filing

IDEXX Laboratories Transcript: Raymond James 46th Annual Institutional Investors Conference

Mar 3, 2025, 11:35 AM EST - 1 year ago

IDEXX Laboratories Transcript: Raymond James 46th Annual Institutional Investors Conference

IDEXX Laboratories Transcript: BofA Securities Animal Health Summit 2025

Feb 27, 2025, 9:00 AM EST - 1 year ago

IDEXX Laboratories Transcript: BofA Securities Animal Health Summit 2025

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

Feb 13, 2025, 2:00 PM EST - 1 year ago

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers.

Feb 3, 2025, 11:31 AM EST - 1 year ago

Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers.

ABBV MOH

IDEXX Laboratories Stock Jumps on Testing Products Demand, Higher Prices

Feb 3, 2025, 11:22 AM EST - 1 year ago

IDEXX Laboratories Stock Jumps on Testing Products Demand, Higher Prices

IDEXX Laboratories Earnings Call Transcript: Q4 2024

Feb 3, 2025, 8:30 AM EST - 1 year ago

IDEXX Laboratories Earnings Call Transcript: Q4 2024

IDEXX Laboratories Annual report: Q4 2024

Feb 3, 2025, 8:30 AM EST - 1 year ago

IDEXX Laboratories Annual report: Q4 2024

IDEXX Laboratories Earnings release: Q4 2024

Feb 3, 2025, 8:30 AM EST - 1 year ago

IDEXX Laboratories Earnings release: Q4 2024

IDEXX Laboratories Slides: Q4 2024

Feb 3, 2025, 8:30 AM EST - 1 year ago

IDEXX Laboratories Slides: Q4 2024

Animal diagnostics maker IDEXX beats quarterly estimates despite low vet visits

Feb 3, 2025, 7:57 AM EST - 1 year ago

Animal diagnostics maker IDEXX beats quarterly estimates despite low vet visits

IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results

Feb 3, 2025, 6:30 AM EST - 1 year ago

IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results

IDEXX Laboratories to Release 2024 Fourth Quarter and Full Year Financial Results

Jan 16, 2025, 4:15 PM EST - 1 year ago

IDEXX Laboratories to Release 2024 Fourth Quarter and Full Year Financial Results

SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX

Dec 19, 2024, 10:09 AM EST - 1 year ago

SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX

SNPS

IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization

Dec 9, 2024, 7:30 AM EST - 1 year ago

IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization

IDEXX Announces CFO Transition

Nov 21, 2024, 7:30 AM EST - 1 year ago

IDEXX Announces CFO Transition

ACVIM and IDEXX Partner to Provide Free Educational Offerings for ACVIM Residents

Nov 12, 2024, 9:00 AM EST - 1 year ago

ACVIM and IDEXX Partner to Provide Free Educational Offerings for ACVIM Residents

CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results

Oct 31, 2024, 1:15 PM EDT - 1 year ago

CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results

IDEXX Laboratories Earnings Call Transcript: Q3 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

IDEXX Laboratories Earnings Call Transcript: Q3 2024

IDEXX Laboratories Quarterly report: Q3 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

IDEXX Laboratories Quarterly report: Q3 2024

IDEXX Laboratories Earnings release: Q3 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

IDEXX Laboratories Earnings release: Q3 2024

IDEXX Laboratories Slides: Q3 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

IDEXX Laboratories Slides: Q3 2024

IDEXX laboratories cuts annual revenue forecast for third time as pet clinic visits slow

Oct 31, 2024, 8:01 AM EDT - 1 year ago

IDEXX laboratories cuts annual revenue forecast for third time as pet clinic visits slow

IDEXX Laboratories to Release 2024 Third Quarter Financial Results

Sep 30, 2024, 2:00 PM EDT - 1 year ago

IDEXX Laboratories to Release 2024 Third Quarter Financial Results

IDEXX Laboratories Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 11:30 AM EDT - 1 year ago

IDEXX Laboratories Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

IDEXX Laboratories to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 21, 2024, 4:15 PM EDT - 1 year ago

IDEXX Laboratories to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

AIBioScanner
AIBioScanner Jun. 8 at 7:58 AM
$IDXX AI-Based Findings on IDXX After running IDXX through my AI-driven quantitative framework, the stock is in a sideways/mixed trend with price trading near both moving averages with no clear directional pressure. IDXX is trading around $562.16, near both the 20-day (~$550.98) and 50-day (~$563.09) moving averages — indicating indecision and softening structure. Key signals: • Trading near both MAs — sideways/mixed trend • MACD negative (-0.26) — bearish momentum • Range between ~$528.68 support and ~$591.84 resistance 1-Month Outlook: Base scenario: consolidation near $534.05–$590.27 Breakout above $590.27 could open a move toward $690.61 Breakdown below $534.05 may extend further downside toward $437.92 Structure is neutral-to-mixed. Requires strong volume confirmation for any reversal. Not financial advice.$IDXX
0 · Reply
MarketBeat
MarketBeat May. 30 at 11:02 AM
https://marketbeat.com/a/8683841/ $IDXX IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference
0 · Reply
BillionerOfKing
BillionerOfKing May. 25 at 9:17 PM
$IDXX Current Stock Price: $559.38 Contracts to trade: $560.0 IDXX Jun 18 2026 Call Entry: $18.00 Exit: $24.97 ROI: 39% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize May. 25 at 2:00 PM
Wall St is expecting 3.96 EPS for $IDXX Q2 [Reporting 08/04 BMO] http://www.estimize.com/intro/idxx?chart=historical&metric_name=eps&utm_co
0 · Reply
CapitalMonk
CapitalMonk May. 20 at 5:49 AM
$IDXX Price: $546.49 (+0.13%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.99% RSI: 46.9 | Momentum: Moderate Volume: +11.3% vs avg Volatility: 2.03% Support: $523.38 | Resistance: $585.12 Sourch: http://marketbaubles.com/
0 · Reply
falcon_trader11
falcon_trader11 May. 18 at 6:15 PM
Not many small biotech names can reference relationships tied to $JNJ and $IDXX . $HYFT ecosystem keeps getting more interesting.
0 · Reply
bullishbears
bullishbears May. 13 at 5:30 PM
Veterinary stocks are gaining attention as pet ownership and animal healthcare spending continue to grow. Companies like Zoetis ($ZTS), IDEXX Laboratories ($IDXX), PetIQ ($PETQ), and Trupanion ($TRUP) are helping shape the future of the veterinary and pet care industry. From diagnostics and pharmaceuticals to pet insurance and wellness products, these stocks give investors exposure to a growing market driven by strong consumer demand and long-term trends. Check out our full breakdown of top veterinary stocks to watch and learn how traders and investors are approaching this sector. https://bullishbears.com/veterinary-stocks/
0 · Reply
MyChicago
MyChicago May. 13 at 4:02 PM
$ZOMDF Zomedica May Momentum CEO Larry Heaton and Johnny D Powers, both added shares in May 2026, direct insider confidence right after Zomedica reported record Q1 revenue of $8.8 million, up 35% YoY with $47.5 million in liquidity. Insiders don’t buy unless they believe in the next leg up. $IDXX $AMZN $ELAN
2 · Reply
Arcides
Arcides May. 11 at 5:02 PM
$IDXX another health care stock with new breakdown...
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 4:44 PM
$IDXX Current Stock Price: $536.65 Contracts to trade: $540.0 IDXX May 15 2026 Call Entry: $6.30 Exit: $9.98 ROI: 58% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
coregamma
coregamma May. 7 at 3:56 PM
These are the businesses who believe AI can negatively impact their business and operations. You can search this yourself on coregamma.io $KLAC $GOOG $DXCM $LYB $ELV $FTV $MSCI $HBAN $HPE $IDXX $HOG $WEC $TEL $ARMK
0 · Reply
BillionerOfKing
BillionerOfKing May. 6 at 10:31 PM
$IDXX Current Stock Price: $579.23 Contracts to trade: $580.0 IDXX May 15 2026 Call Entry: $11.20 Exit: $18.62 ROI: 66% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize May. 5 at 6:24 PM
$IDXX reported 3.47 EPS and 1,141 revenue for Q1. http://www.estimize.com/intro/idxx?chart=historical&metric_name=eps&utm_content=IDXX&utm_
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 10:38 AM
$IDXX Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $3.50 up 17.45% YoY • Reported revenue of $1.14B up 14.26% YoY • Idexx Laboratories increased its 2026 revenue guidance to $4.68B - $4.76B, reflecting stronger CAG Diagnostics performance. The company also raised its 2026 EPS outlook to $14.45 - $14.90 and projected operating margin expansion to 50-90 basis points.
0 · Reply
CapitalMonk
CapitalMonk May. 4 at 1:15 PM
$IDXX Price: $567.46 (+1.19%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.22% RSI: 47.7 | Momentum: Moderate Volume: +14.5% vs avg Volatility: 2.07% Support: $544.01 | Resistance: $605.82 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
topstockalerts
topstockalerts Apr. 28 at 12:15 PM
Pre Market Top Gainers PT2 $NEXR $NDRA $IDXX $DDI $LGIH
0 · Reply
topstockalerts
topstockalerts Apr. 28 at 10:58 AM
Pre Market Top Gainers $DRCT $PFSA $KIDZ $NWGL $IDXX
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 28 at 1:21 AM
$IDXX Share Price: $575.16 Contract Selected: Oct 16, 2026 $580 Calls Buy Zone: $48.02 – $59.33 Target Zone: $84.39 – $103.14 Potential Upside: 66% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
roblake29
roblake29 Apr. 22 at 5:04 PM
$IDXX $ZTS Here's a link to my latest analysis, a deep-dive comparison of Idexx Labs and Zoetis. Interestingly, they both get a buy rating from me, but for different reasons. Constructive feedback welcome: https://seekingalpha.com/article/4892880-idexx-laboratories-vs-zoetis-a-pre-earnings-comparison
0 · Reply
DonCorleone77
DonCorleone77 Apr. 7 at 11:40 AM
$ELAN $IDXX $ZTS $TRUP $CHWY Attached is a page from a Piper Sandler analyst report regarding ELAN, IDXX, ZTS, TRUP and CHWY issued 4.2.26
0 · Reply
txbondman
txbondman Mar. 30 at 1:00 PM
bot $BABA, $CVCO, and $IDXX to double down; (Don't try this at home!!)
0 · Reply
MyChicago
MyChicago Mar. 27 at 9:24 PM
$ZOMDF Paul Tye, Great News to have Mr Tye on board. High Expectations for Zomedicas global expansion in their International Markets. Paul Tye was also with IDXX and Mars. $IDXX Excited to see the Premium Equine Market and Racing that Zomedica is built to serve with their diagnostics and therapeutics. The Stall Side ACTH test and Insulin level tests are truly a game changer, and Zomedica is the only company right now that offers this. There are 9.2 Million horses in the U.S.A. Zomedica has 53.3 Million dollars in cash. No Debt. Great Reduction in Cash Burn, I believe It is their lowest ever. Larry states they have enough cash to to accomplish their goals to profitability by end of this year or definitely next. He was very straight forward about this and feels certain that we will be cash flow positive Very Soon. There is not a better time buy. BULLISH.
0 · Reply